Advertisement

Zusammenfassung

Cholinesterasehemmer haben nach einem erneuten kräftigen Verordnungszuwachs einen Anteil von 10% am Verordnungsvolumen der Antidementiva nach definierten Tagesdosen erreicht. Die Verordnungen des NMDA-Antagonisten Memantin nahmen dagegen leicht ab. Ginkgoextrakte sind weiter rückläufig, bleiben abertrotz ungenügender Beleglage die führende Präparategruppe mit über 50 % der Verordnungen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. AD2000 Collaborative Group (2004): Long-term donepezil treatment in 565 patients with Alzheimer’s disease (AD2000): randomised double-blind trial. Lancet 363: 2105–2115.CrossRefGoogle Scholar
  2. Areosa SA, Sherriff F (2003): Memantine for dementia. Cochrane Database Syst Rev 3: CD003154.Google Scholar
  3. Arzneimittelkommission der Deutschen Ärzteschaft (2001): Empfehlungen zur Therapie der Demenz. Arzneiverordnung in der Praxis, Sonderheft, 2. Auflage.Google Scholar
  4. Bickel H (2001): Demenzen im höheren Lebensalter: Schätzungen des Vorkommens und der Versorgungskosten. Z Gerontol Geriat 34: 108–115.CrossRefGoogle Scholar
  5. Birks J, Grimley EV, Van Dongen M (2002): Ginkgo biloba for cognitive impairment and dementia. Cochrane Database Syst Rev (4): CD003120.Google Scholar
  6. Birks J, Iakovidou V, Tsolaki M (2000): Rivastigmine for Alzheimer’s disease. Cochrane Database Syst Rev 2: CD001191.Google Scholar
  7. Birks JS, Melzer D, Beppu H (2002): Donepezil for mild and moderate Alzheimer’s disease (Cochrane-Review). The Cochrane Library, Issue 2, 2002, Oxford: Updated Software.Google Scholar
  8. Birmingham K, Frantz S (2002): Set back to Alzheimer vaccine studies. Nature Med 8: 199–200.PubMedGoogle Scholar
  9. Burns A, Rossor M, Hecker J, Gauthier S, Petit H, Möller HJ, Rogers SL, Friedhoff LT and the International Donepezil Study Group (1999): The effects of donepezil in Alzheimer’s disease — results from a multinational trial. Dement Geriatr Cogn Disord 10: 237–244.PubMedCrossRefGoogle Scholar
  10. Committee for Proprietary Medicinal Products (CPMP) (1998): Note for guidance on medicinal products in the treatment of Alzheimer’s disease.Google Scholar
  11. Corey-Bloom J, Anand R, Veach J for the ENA 713 B352 Study Group (1998): A randomized trial evaluating the efficacy and safety of ENA 713 (rivastigmine tartrate), a new acetylcholinesterase inhibitor, in patients with mild to moderately severe Alzheimer’s disease. Int J Geriatr Psychopharmacol 1: 55–65.Google Scholar
  12. Croisile B, Trillet M, Fondarai J, Laurent B, Mauguiere F, Billardon M (1993): Long-term and high-dose piracetam treatment of Alzheimer’s disease. Neurology 43: 301–305.PubMedCrossRefGoogle Scholar
  13. Cummings JL (2004): Alzheimer’s disease. N Engl J Med 351: 56–67.PubMedCrossRefGoogle Scholar
  14. Davies P, Maloney AJ (1976): Selective loss of central cholinergic neurons in Alzheimer’s disease. Lancet 2: 1403.PubMedCrossRefGoogle Scholar
  15. Dodel RC, Hampel H, Du Y (2003): Immunotherapy for Alzheimer’s disease. Lancet Neurology 2: 215–220.PubMedCrossRefGoogle Scholar
  16. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L et al (2001): Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 56: 1154–1166.PubMedCrossRefGoogle Scholar
  17. Drew S, Davies E (2001): Effectiveness of Ginkgo biloba in treating tinnitus: double blind, placebo controlled trial. Brit Med J 322: 1–6.CrossRefGoogle Scholar
  18. Fioravanti M, Flicker L (2001): Efficacy of nicergoline in dementia and other age associated forms of cognitive impairment. Cochrane Database Syst Rev 2001(4): CD003159.Google Scholar
  19. Food and Drug Administration (1989): Peripheral and Central Nervous System Drugs Advisory Committee Meeting, July 7, 1989. Rockville MD: Dept. of Health and Human Services, Public Health service 1989: 227.Google Scholar
  20. Forette F, Anand R, Gharabawi G (1999): A phase II study in Patients with Alzheimer’s disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon®). Eur J Neurol 6: 423–429.PubMedCrossRefGoogle Scholar
  21. Gaitz CM, Varner RV, Overall JE (1977): Pharmacotherapy for organic brain syndrome in late life. Evaluation of an ergot derivative vs placebo. Arch Gen Psychiatry 34: 839–845.PubMedCrossRefGoogle Scholar
  22. Geldmacher DS, Provenzano G, McRae T, Mastey V, Ieni JR (2003): Donepezil is associated with delayed nursing home placement in patients with Alzheimer’s disease. J Am Geriatr Soc 51: 937–44.PubMedCrossRefGoogle Scholar
  23. Hollister L, Gruber N (1996): Drug treatment of Alzheimer’s disease. Effects on caregiver burden and patient quality of life. Drugs Aging 8: 47–55.PubMedCrossRefGoogle Scholar
  24. In’t Veld BA, Riutenberg A, Hofman A, Launer LJ, van Duijn CM, Stijnen T et al (2001): Nonsteroidal antiinflammatory drugs and the risk of Alzheimer’s disease. N Engl J Med 345: 1515–1521.CrossRefGoogle Scholar
  25. Kanowski S, Herrmann WM, Stephan K, Wierich W, Hörr R (1996): Proof of efficacy of the Ginkgo biloba special extract Egb 761 in outpatients suffering from mild to moderate primary degenerative dementia of the Alzheimer type or multi-infarct dementia. Pharmacopsychiatry 29: 47–56.PubMedCrossRefGoogle Scholar
  26. Kleijnen J, Knipschild P (1992): Ginkgo biloba. Lancet 340: 1136–1139.PubMedCrossRefGoogle Scholar
  27. Kugler J, Oswald WD, Herzfeld U, Seus R, Pingel J, Welzel D (1978): Langzeittherapie altersbedingter Insuffizienzerscheinungen des Gehirns. Dtsch Med Wochenschr 103: 456–462.PubMedCrossRefGoogle Scholar
  28. Lanctot KL, Herrmann N, Yau KK, Khan LR, Liu BA, LouLou MM, Einarson TR (2003): Efficacy and safety of Cholinesterase inhibitors in Alzheimer’s disease: a meta-analysis. Canad Med Ass J 169: 557–564.Google Scholar
  29. Le Bars PL, Katz MM, Berman N, Itil TM, Freedman AM, Schatzberg AF (1997): A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA 278: 1327–1332.PubMedCrossRefGoogle Scholar
  30. Lopez OL, Becker JT, Wisniewski S, Saxton J, Kaufer DI, DeKosky ST (2002): Cholinesterase inhibitor treatment alters the natural history of Alzheimer’s disease. J Neurol Neurosurg Psychiatry 72: 310–14.PubMedCrossRefGoogle Scholar
  31. Marin DB, Davis KL (1995): Experimental therapeutics. In: Bloom FE, Kupfer DJ (eds): Psychopharmacology: The fourth generation of progress. Raven Press Ltd, New York, pp 1417–1426.Google Scholar
  32. Matthews HP, Korbey J, Wilkinson DG Rowden J (2000): Donepezil in Alzheimer’s disease: eighteen month results from Southampton Memory Clinic. Int J Geriatr Psychiatry 15: 713–20.PubMedCrossRefGoogle Scholar
  33. Mix JA, Crews WD Jr (2002): A double-blind, placebo-controlled, randomized trial of Ginkgo biloba exctract EGb 761 in a sample of cognitively intact older adults: neuropsychological findings. Hum Psychopharmacol 17: 267–277.PubMedCrossRefGoogle Scholar
  34. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD for the „312“ Study Group (2001): A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. Neurology 57: 481–488.PubMedCrossRefGoogle Scholar
  35. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R et al (2000): Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease. JAMA 283: 1007–1015.PubMedCrossRefGoogle Scholar
  36. Nicoll JAR, Wilkinson D, Holmes C, Steart P, Markham H, Weller RO (2003): Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report. Nature Med 9: 448–452.PubMedCrossRefGoogle Scholar
  37. O’Brien JT, Ballard CG (2001): Drugs for Alzheimer’s disease. Brit Med J 323: 123–124.CrossRefGoogle Scholar
  38. Olin J, Schneider L (2002): Galantamine for Alzheimer’s disease (Cochrane Review). In: Cochrane Library, Issue 1, 2002 Oxford: Update Software.Google Scholar
  39. Orgogozo J-M, Rigaud A-S, Stöffler A, Möbius HJ, Forette F (2002): Efficacy and safety of memantine in patients with mild to moderate vascular dementia. A randomized, placebo-controlled trial (MMM 300). Stroke 33: 1834–1839.PubMedCrossRefGoogle Scholar
  40. Raskind MA, Peskind ER, Wessel T, Yuan W and the Galantamine USA-1 Study Group (2000): A 6-month randomized, placebo-controlled trial with a 6-month extension. Neurology 54: 2261–2268.PubMedCrossRefGoogle Scholar
  41. Reisberg B, Doody R, Stöffler A, Schmitt F, Ferris S, Möbius HJ for the Memantine Study Group (2003): Memantine in moderate-to-severe Alzheimer’s disease. N Engl J Med 348: 1333–1341.PubMedCrossRefGoogle Scholar
  42. Reines SA, Block GA, Morris JC, Liu G, Nessly ML et al (2004): Rofecoxib. No effect on Alzheimer’s disease in a 1-year, randomized, blinded, controlled study. Neurology 62: 66–71.PubMedCrossRefGoogle Scholar
  43. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT and the Donepezil Study Group (1998): A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer’s disease. Neurology 50: 136–145.PubMedCrossRefGoogle Scholar
  44. Sano M, Ernesto C, Thomas RG, Klauber MR, Schafer K, Grundman M et al for the Members of the Alzheimer’s Disease Cooperative Study (1997): A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer’s disease. N Engl J Med 336: 1216–1222.PubMedCrossRefGoogle Scholar
  45. Schellenberg R, Todorova A, Wedekind W, Schober F, Dimpfel W (1997): Pathophysiology and psychopharmacology of dementia — a new study design. 2. Cyclan-delate treatment — a placebo-controlled double-blind clinical trial. Neuropsy-chobiology 35: 132–142.Google Scholar
  46. Schneider LS (2004): AD2000: donepezil in Alzheimer’s disease. Lancet 363: 2100–2101.PubMedCrossRefGoogle Scholar
  47. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB Ockene JK et al for the WHIMS Investigators (2003): Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. The Women’s Health Initiative Memory Study: a randomized controlled trial. JAMA 289: 2651–2662.PubMedCrossRefGoogle Scholar
  48. Solomon PR, Adams F, Silver A, Zimmer J, DeVeaux R (2002): Ginkgo for memory enhancement: a randomized controlled trial. JAMA 288: 835–840.PubMedCrossRefGoogle Scholar
  49. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I for the Memantine Study Group (2004): Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil. JAMA 291: 317–324.PubMedCrossRefGoogle Scholar
  50. Tariot PN, Solomon PR, Morris JC, Kershaw P, Lilienfeld S, Ding C et al (2000): A 5-month, randomized, placebo-controlled trial of galantamine in AD. Neurology 54: 2269–2276.PubMedCrossRefGoogle Scholar
  51. Thompson TL II, Filley CM, Mitchell WD, Culig KM, LoVerde M, Byyny RL (1990): Lack of efficacy of hydergine in patients with Alzheimer’s disease. N Engl J Med 323: 445–448.PubMedCrossRefGoogle Scholar
  52. Van Dongen MCJM, van Rossum E, Kessels AGH, Sielhorst HJG, Knipschild PG (2000): The efficacy of ginkgo for elderly people with dementia and age-associated memory impairment: new results of a randomized clinical trial. J. Am Ger Soc 48: 1183–1194.Google Scholar
  53. Vernon MW, Sorkin EM (1991): Piracetam. An overview of its pharmacological properties and a review of its therapeutic use in senile cognitive disorders. Drugs Aging 1: 17–35.PubMedCrossRefGoogle Scholar
  54. Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wimo A et al and the Donepezil Nordic Study Group (2001): A 1-year, randomised, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 57: 489–495.PubMedCrossRefGoogle Scholar
  55. Winblad B, Poritis N (1999): Memantine in severe dementia: results of the 9M-Best Study (Benefit and efficacy in severely demented patients during treatment with memantine). Int J Geriat Psychiatry 14: 135–146.CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Ulrich Schwabe
    • 1
  1. 1.Pharmakologisches Institut der Universität HeidelbergHeidelberg

Personalised recommendations